规格 | 价格 | 库存 | 数量 |
---|---|---|---|
250mg |
|
||
500mg |
|
||
1g |
|
||
2g |
|
||
5g |
|
||
10g |
|
||
Other Sizes |
|
体外研究 (In Vitro) |
葡萄籽提取物(25-100 μg/mL;12-48 小时)可抑制人结直肠癌细胞的生长并导致其死亡[3]。葡萄籽提取物(25-100 μg/mL;12-24 小时)可调节控制 HT29 和 LoVo 细胞细胞周期的分子的蛋白质水平[3]。葡萄籽提取物(25-100 μg/mL;24 小时)导致人结直肠癌细胞发生细胞凋亡[3]。
|
---|---|
体内研究 (In Vivo) |
葡萄籽提取物(200 mg/kg;ig;5 天/周;持续 8 周)抑制无胸腺裸鼠中 HT29 结肠癌异种移植物的生长[3]。在肿瘤中,葡萄籽提取物会减少细胞增殖,同时增加细胞凋亡[3]。在肿瘤中,葡萄籽提取物可增加聚 (ADP-核糖) 聚合酶的裂解和 Cip1/p21 蛋白水平 [3]。
|
动物实验 |
Athymic male nu/nu mice, with human colon carcinoma HT29 tumor xenograft[3]
200 mg/kg Oral gavage, 5 days/wk, for 8 weeks |
参考文献 |
分子式 |
C₃₀H₁₂O₆
|
|
---|---|---|
分子量 |
468.42
|
|
CAS号 |
84929-27-1
|
|
相关CAS号 |
|
|
外观&性状 |
Solid
|
|
SMILES |
CC1=CC(=C(C2=C1C[C@@]([C@H](O2)C3=CC(=C(C=C3)O)O)(C)O)[C@H]4[C@@H]([C@H](OC5=CC(=CC(=C45)O)O)C6=CC(=C(C=C6)O)O)O)O
|
|
InChi Key |
VWKAFYWVDIOMSL-PMFFMQSYSA-N
|
|
InChi Code |
InChI=1S/C32H30O11/c1-13-7-22(38)26(30-17(13)12-32(2,41)31(43-30)15-4-6-19(35)21(37)9-15)27-25-23(39)10-16(33)11-24(25)42-29(28(27)40)14-3-5-18(34)20(36)8-14/h3-11,27-29,31,33-41H,12H2,1-2H3/t27-,28-,29+,31+,32+/m0/s1
|
|
化学名 |
(2R,3S,4S)-2-(3,4-dihydroxyphenyl)-4-[(2R,3R)-2-(3,4-dihydroxyphenyl)-3,7-dihydroxy-3,5-dimethyl-2,4-dihydrochromen-8-yl]-3,4-dihydro-2H-chromene-3,5,7-triol
|
|
别名 |
|
|
存储方式 |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
运输条件 |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
溶解度 (体外) |
|
|||
---|---|---|---|---|
溶解度 (体内) |
Solubility in Formulation 1: ≥ 0.6 mg/mL (Infinity mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 6.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 0.6 mg/mL (Infinity mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 6.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. 请根据您的实验动物和给药方式选择适当的溶解配方/方案: 1、请先配制澄清的储备液(如:用DMSO配置50 或 100 mg/mL母液(储备液)); 2、取适量母液,按从左到右的顺序依次添加助溶剂,澄清后再加入下一助溶剂。以 下列配方为例说明 (注意此配方只用于说明,并不一定代表此产品 的实际溶解配方): 10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline); 假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀/澄清;向上述体系中加入50 μL Tween-80,混合均匀/澄清;然后继续加入450 μL ddH2O (或 saline)定容至 1 mL; 3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例; 4、 如产品在配制过程中出现沉淀/析出,可通过加热(≤50℃)或超声的方式助溶; 5、为保证最佳实验结果,工作液请现配现用! 6、如不确定怎么将母液配置成体内动物实验的工作液,请查看说明书或联系我们; 7、 以上所有助溶剂都可在 Invivochem.cn网站购买。 |
制备储备液 | 1 mg | 5 mg | 10 mg | |
1 mM | 2.1348 mL | 10.6742 mL | 21.3484 mL | |
5 mM | 0.4270 mL | 2.1348 mL | 4.2697 mL | |
10 mM | 0.2135 mL | 1.0674 mL | 2.1348 mL |
1、根据实验需要选择合适的溶剂配制储备液 (母液):对于大多数产品,InvivoChem推荐用DMSO配置母液 (比如:5、10、20mM或者10、20、50 mg/mL浓度),个别水溶性高的产品可直接溶于水。产品在DMSO 、水或其他溶剂中的具体溶解度详见上”溶解度 (体外)”部分;
2、如果您找不到您想要的溶解度信息,或者很难将产品溶解在溶液中,请联系我们;
3、建议使用下列计算器进行相关计算(摩尔浓度计算器、稀释计算器、分子量计算器、重组计算器等);
4、母液配好之后,将其分装到常规用量,并储存在-20°C或-80°C,尽量减少反复冻融循环。
计算结果:
工作液浓度: mg/mL;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL)。如该浓度超过该批次药物DMSO溶解度,请首先与我们联系。
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
(1) 请确保溶液澄清之后,再加入下一种溶剂 (助溶剂) 。可利用涡旋、超声或水浴加热等方法助溶;
(2) 一定要按顺序加入溶剂 (助溶剂) 。
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT03087903 | Active Recruiting |
Dietary Supplement: Grape Seed Extract |
Prostate Cancer | University of Colorado, Denver |
January 18, 2018 | Not Applicable |
NCT00713167 | Active Recruiting |
Drug: Grape Seed Extract (Vitagrape) Drug: Placebo of Grape Seed Extract |
Hyperlipidemia | Shahid Beheshti University of Medical Sciences |
July 2008 | Phase 2 Phase 3 |
NCT01185067 | Completed | Drug: grape seed extract | Hypertension Oxidative Stress |
University of Michigan | October 2010 | Phase 1 |
NCT04136639 | Completed | Other: Miswak Other: fluoride |
Dental Caries | Al-Azhar University | June 1, 2019 | Not Applicable |
NCT01820299 | Completed | Drug: Grape Seed Extract Drug: Vitamin D |
Solid Cancers | Medical University of South Carolina |
March 2013 | Phase 1 |